New drug shows promise for Hard-to-Treat breast cancer in Real-World study
NCT ID NCT07347600
First seen Jan 21, 2026 · Last updated May 09, 2026 · Updated 10 times
Summary
This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The cancer must have a specific gene change (PIK3CA mutation) and be hormone receptor-positive and HER2-negative. About 500 people in China will take inavolisib as part of their regular care, and researchers will track how long the cancer stays under control and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing Cancer Hospital
RECRUITINGChongqing, 400030, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
-
Gansu Provincial Maternal and Child Health Hospital (Gansu Provincial Hospital of Traditional Chinese Medicine)
RECRUITINGLanzhou, Gansu, 730050, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, 150081, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, 430079, China
-
Jiangsu Province Hospital
RECRUITINGNanjing, 210029, China
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, 330006, China
-
Peking University First Hospital
RECRUITINGBeijing, 100034, China
-
Peking University Third Hospital
RECRUITINGBeijing, 100191, China
-
Shandong Provincial Hospital
RECRUITINGJinan, 250021, China
-
Shanxi Provincial Cancer Hospital
RECRUITINGTaiyuan, 030013, China
-
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
RECRUITINGChengdu, 610072, China
-
Subei People's Hospital of Jiangsu province
RECRUITINGYangzhou, 225001, China
-
Taizhou Hospital of Zhejiang Province
RECRUITINGTaizhou, 317000, China
-
Weifang People's Hospital
RECRUITINGWeifang, 261041, China
-
Wenzhou Medical University Affiliated Second Hospital
RECRUITINGWenzhou, Zhejiang, 325000, China
-
Zhujiang Hospital, Southern Medical University
RECRUITINGGuangzhou, 510280, China
Conditions
Explore the condition pages connected to this study.